BLCO Bausch + Lomb Corp.Watchlist
Bausch + Lomb Corp. News
Bausch + Lomb Reports More Than 76 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue Eye Care Recycling Programs
Bausch + Lomb Corporation's (NYSE:BLCO) Revenues Are Not Doing Enough For Some Investors
You may think that with a price-to-sales (or "P/S") ratio of 1.5x Bausch + Lomb Corporation (NYSE:BLCO) is a stock worth checking out, seeing as almost half of all the Medical Equipment companies in the United States have P/S ratios greater than 3x and even P/S higher than 6x aren't out of the ordinary.
Bausch & Lomb Corp (BLCO) Reports Q3 2023 Earnings and Raises Full-Year Guidance
Earnings Scheduled For November 1, 2023
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion. • Ballys (NYSE:BALY) is estimated to report quarterly loss
Express News | Bausch & Lomb Raised FY23 Revenue Outlook To $4.035B-$4.085B (From $3.95B-$4.00B) Vs. $5.51B Est
Bausch & Lomb Q3 Adj. EPS $0.22 Misses $0.26 Estimate, Sales $1.01B Miss $1.36B Estimate
Bausch & Lomb (NYSE:BLCO) reported quarterly adjusted earnings of $0.22 per share which missed the analyst consensus estimate of $0.26 by 15.38 percent. This is a 29.03 percent decrease over earnings
Bausch & Lomb Earnings Preview
Bausch & Lomb (NYSE:BLCO) is set to give its latest quarterly earnings report on Wednesday, 2023-11-01. Here's what investors need to know before the announcement.Analysts estimate that Bausch & Lomb
RBC Trims Price Target on Bausch + Lomb to $20 From $21 Amid Foreign-Exchange Headwinds, Keeps Outperform Rating
Bausch + Lomb (BLCO) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $18 to $25.87.
Bausch + Lomb Will Release Third-Quarter 2023 Financial Results on November 1
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2023 financial results on Wednesday, Nov. 1, 2023. Bausch +
Morgan Stanley Maintains Equal-Weight on Bausch & Lomb, Lowers Price Target to $18.5
Morgan Stanley analyst Patrick Wood maintains Bausch & Lomb (NYSE:BLCO) with a Equal-Weight and lowers the price target from $20 to $18.5.
HC Wainwright & Co. Reiterates Buy on Bausch & Lomb, Lowers Price Target to $21
HC Wainwright & Co. analyst Yi Chen reiterates Bausch & Lomb (NYSE:BLCO) with a Buy and lowers the price target from $22 to $21.
Novartis Mulls Divesting Some Assets Of Radiopharma Unit In Strategic Shift
Swiss pharmaceutical giant Novartis AG (NYSE:NVS) is reportedly contemplating selling sections of radiopharmaceuticals company Advanced Accelerator Applications to align with the company's strategy an
6 Analysts Have This to Say About Bausch & Lomb
Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings within the last quarter: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings22200Last 30D010001M Ago000002M Ago1
Evercore ISI Group Reinstates Outperform on Bausch & Lomb, Announces $20 Price Target
Evercore ISI Group analyst Vijay Kumar reinstates Bausch & Lomb (NYSE:BLCO) with a Outperform and announces $20 price target.
Bausch + Lomb Completes Acquisition of Xiidra, Other Ophthalmology Assets From Novartis for Up To $2.5 Billion
Bausch Health's (BHC) Bausch + Lomb (BLCO) unit said Friday it has completed its acquisition of dry eye drop Xiidra and certain other ophthalmology assets from Novartis (NVS) for as much as $2.5 milli
Bausch + Lomb Completes Acquisition of XIIDRA
Poised for Significant Growth in Prescription Dry Eye Segment Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has
Bausch + Lomb Introduces New Hypoallergenic Eye Care Range Lumify
Bausch + Lomb (BLCO) said Tuesday it has introduced a new range of hypoallergenic specialty eye care products in the US, known as Lumify Eye Illuminations. The product line includes a micellar cleansi
Bausch + Lomb Launches LUMIFY EYE ILLUMINATIONS in the United States
Bausch Health Stock Rebounds From Tuesday Sell-off, Helped by Jefferies Upgrade
Bausch + Lomb's ONE by ONE and Biotrue Eye Care Recycling Programs Recognized As Sustainability Service of the Year Award Winners